Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Obinutuzumab: what is there to learn from clinical trials?

Guillaume Cartron, Hervé Watier

Blood (2017) 130 (5): 581–589.

https://doi.org/10.1182/blood-2017-03-771832

Published: 2017

Journal Articles

Bacteria and HIT: a close connection?

Yves Gruel, Hervé Watier

Blood (2011) 117 (4): 1105–1106.

https://doi.org/10.1182/blood-2010-11-317941

Published: 2011

Journal Articles

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

David Daydé, David Ternant, Marc Ohresser, Stéphanie Lerondel, Sabrina Pesnel, Hervé Watier, Alain Le Pape, Pierre Bardos, Gilles Paintaud, Guillaume Cartron

Blood (2009) 113 (16): 3765–3772.

https://doi.org/10.1182/blood-2008-08-175125

Published: 2009

Journal Articles

Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.

Olivier Herault, MD, PhD, Florence Dommange, MD, Claire Espanel, MD, Jorge Domenech, MD, PhD, Lotfi Benboubker, MD, PhD, Marc Ohresser, PhD, Philippe Colombat, MD, Christian Binet, MD, Herve Watier, MD, PhD, Guillaume Cartron, MD, PhD

Blood (2004) 104 (11): 66.

https://doi.org/10.1182/blood.V104.11.66.66

Published: 2004

Journal Articles

Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.

Caroline Dartigeas, MD, Michel Degenne, PharmD, Delphine Senecal, MD, Philippe Roingeard, PhD, Chantal Cendrie, MD, Martine Delain, MD, Lotfi Benboubker, MD PhD, Claude Linassier, MD PhD, Herve Watier, MD PhD, Christian Binet, MD, Philippe Colombat, MD, Guillaume Cartron, MD PhD

Blood (2004) 104 (11): 2509.

https://doi.org/10.1182/blood.V104.11.2509.2509

Published: 2004

NARROW

Obinutuzumab: what is there to learn from clinical trials?

Bacteria and HIT: a close connection?

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.

Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Obinutuzumab: what is there to learn from clinical trials?

Bacteria and HIT: a close connection?

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.

Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only